Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The CAPER Study: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma (RCC) (CAPER Trial)

NCT04262427 is registered in ClinicalTrials.gov with The Christie NHS Foundation Trust as lead sponsor.

NCT NCT04262427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04262427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The CAPER Study: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma (RCC) (CAPER Trial)
Lead sponsor
The Christie NHS Foundation Trust
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 28, 2021
Completion date
April 28, 2024
Enrollment
21 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma